DA-020 topically for chemotherapy-induced hair loss
Official title: Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Run by Applied Biology, Inc. · NCT07397325 · Data updated 2026-11-12
This study tests DA-020 (a topical alpha-1 agonist) to see if it can reduce hair loss in people with breast cancer receiving certain chemotherapies.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Applied Biology, Inc. Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Manaus and 1 other locations) |
| Status | Recruiting |
| Started | May 16, 2026 |
| Main results expected | February 5, 2027 |
| Study ends | March 5, 2027 |
| Registry record updated | August 21, 2026 |
| Trial ID | NCT07397325 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18-65 with early-stage breast cancer starting taxane- or anthracycline-based chemotherapy, and no scalp or blood pressure exclusions that would interfere with the topical treatment.
✕Probably not a fit
Patients with uncontrolled hypertension, active scalp disorders, or those already wearing wigs prior to chemotherapy may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study combines Phase 1 and Phase 2 phases to evaluate a topical alpha-1 agonist (DA-020) for reducing chemotherapy-induced alopecia. Participants are adults with stage I-II breast cancer who are about to start taxane- or anthracycline-based chemotherapy. The study compares DA-020 alone, placebo, and a combination of DA-020 with hyperforin to see if scalp perfusion can be reduced and hair loss minimized. Outcomes will include measures of hair retention and safety, with attention to eligible scalp conditions and blood pressure criteria. Locations include Hospital Samel in Manaus and the University of Rome, reflecting a multi-center approach.
Why it matters
Potential benefit: If successful, DA-020 could help patients retain hair during chemotherapy, reducing psychological burden and improving quality of life.
How similar studies have gone: Prior scalp cooling approaches have shown some benefit in reducing CIA, supporting exploration of topical alpha-1 agonists as an alternative.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with stage I or stage II breast cancer * Scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy. * Ages 18-65 * Able to give informed consent Exclusion Criteria: * Resting blood pressure outside the range of 105-140/ 55-99 * Uncontrolled or severe hypertension * Female pattern hair loss or hair loss disorder * Folliculitis * Scalp psoriasis * Seborrheic dermatitis * Inflammatory scalp conditions such as lichen planopillaris * Subjects wearing wigs prior to chemotherapy * Use of MAO inhibitors * Unable to provide consent or make allotted clinical visits
Where it's running
-
Hospital Samel
Manaus, Brazil Recruiting -
University of Rome ("G. Marconi")
Rome, Italy Not yet recruiting
Study contacts
- Study coordinator: Andy Goren, MD
- Email: clinicalstudies@appliedbiology.com
- Phone: 16507040850
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-powered mobile app to help breast cancer patients manage chemotherapy symptoms
A mobile app with artificial intelligence is being tested to see if it helps women with breast cancer manage chemotherapy symptoms and feel more confident in their care.
-
Education on chemotherapy side effects via social media for breast cancer patients
This study tests if teaching breast cancer patients about chemotherapy side effects through social media videos helps them understand the information better than traditional handouts.
-
Testing the Lily Device for reducing hair loss during chemotherapy
This study is testing the Lily Device to see if it can help women with breast cancer keep their hair during chemotherapy.
-
Comparing total neoadjuvant therapy with surgery for rectal cancer treatment
This study is testing if rectal cancer patients who respond well to a new treatment can skip surgery and just be monitored to see how they do compared to those who have surgery right away.
-
Remote physical activity program for cancer survivors with and without diabetes
This study is trying out a remote exercise program for cancer survivors, with and without diabetes, to see if it can help improve their quality of life and cognitive skills after chemotherapy.
-
Assessing and managing taste changes in cancer patients undergoing chemotherapy
This study is testing if a special program led by nurses can help cancer patients undergoing chemotherapy better manage changes in their taste and feel more in control of their symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.